CEL-SCI Announces Change of Location to 2020 Annual Meeting of Shareholders
VIENNA, Va.--(BUSINESS WIRE)-- CEL-SCI Corporation (NYSE American: CVM), announced today that the location of its 2020 Annual Meeting of Shareholders will be changed and a virtual format via a live online webcast will be added. The annual stockholders meeting, which was previously announced in CEL-SCI’s Notice of 2020 Annual Meeting and Proxy Statement and filed with the Securities and Exchange Commission (“SEC”) on March 4, 2020, will still be held on April 17, 2020 at 10:30 a.m. ET, but in a hybrid meeting format. Because of the social distancing requirements and the government imposed limit on the number of people in any meeting, we strongly encourage you to attend the meeting through the live online webcast.
Due to the emerging public health impact of the coronavirus outbreak (COVID-19) and to support the health and well-being of its employees, shareholders, and the community, the Company has made the decision to change the location and format of the 2020 Annual Meeting of Shareholders to a hybrid meeting. The new location of the upcoming meeting will be 8229 Boone Blvd., Suite 802, Vienna, VA 22182 and via a live online webcast.
Stockholders of record at the close of business on February 21, 2020 will be able to access the 2020 Annual Meeting webcast online at http://www.meetingcenter.io/291292248. You will be required to enter your 16-digit control number provided in your proxy material and a password. The password for the meeting is CVM2020.
If you hold your shares through an intermediary, such as a bank or broker, you must register in advance to attend the Annual Meeting online. To register you must submit proof of your proxy power (legal proxy) reflecting your CEL-SCI holdings along with your name and email address to Computershare. Requests for registration must be labeled as “Legal Proxy” and be received no later than 5:00 p.m., ET, on April 12, 2020. Forward the email from your broker, or attach an image of your legal proxy, to firstname.lastname@example.org. You will receive a confirmation email from Computershare of your registration.
Please note that the proxy card included with the proxy materials previously distributed will not be updated to reflect the change in location and may continue to be used to vote your shares in connection with the Annual Meeting.
If you have already voted your shares, and you do not want to change your vote, there is nothing further you need to do and your vote will be counted at the meeting. We encourage you to attend the annual meeting via the webcast. Geert Kersten, the Company’s Chief Executive Officer, will be presiding at the annual meeting and expects to answer questions submitted by shareholders.
About CEL-SCI Corporation
CEL-SCI is a clinical-stage biotechnology company focused on finding the best way to activate the immune system to fight cancer and infectious diseases. The Company’s lead investigational therapy Multikine is currently in a pivotal Phase 3 clinical trial involving head and neck cancer, for which the Company has received Orphan Drug Status from the FDA. The Company’s LEAPS technology is being developed for rheumatoid arthritis and as a potential treatment of COVID-19 in hospitalized patients. The Company has operations in Vienna, Virginia, and near Baltimore, Maryland.
This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including statements with respect to Multikine and the Phase 3 clinical trial of Multikine in patients with advanced primary squamous cell carcinoma of the head and neck. When used in this press release, the words "intends," "believes," "anticipated," "plans" and "expects," and similar expressions, are intended to identify forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Factors that could cause or contribute to such differences include, an inability to duplicate the clinical trials or nonclinical results demonstrated in clinical studies, timely development of any potential products that can be shown to be safe and effective, receiving necessary regulatory approvals, difficulties in manufacturing any of the Company's potential products, inability to raise the necessary capital and the risk factors set forth from time to time in CEL-SCI's filings with the Securities and Exchange Commission, including but not limited to its report on Form 10-K/A for the year ended September 30, 2019 and its recently filed prospectus supplement. The Company undertakes no obligation to publicly release any revision to these forward-looking statements which may be made to reflect the events or circumstances after the date hereof or to reflect the occurrence of unanticipated events.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200330005626/en/
Gavin de Windt
Source: CEL-SCI Corporation
View this news release online at: